Fig. 9: Cotreatment with HPA-12 and Creno is effective in FLT3-ITD⁺ and FLT3-TKD⁺ AML patient-derived cells.

a Viability of primary FLT3-ITD⁺ AML blasts treated with increasing concentrations of HPA-12 (0, 60, 80, and 100 μM) for 48 h. Cell viability was measured by the CCK-8 assay. Viability of FLT3-ITD⁺ CD34⁺ primary AML cells (b) and CD34⁺ hematopoietic stem and progenitor cells (c). CD34⁺ cells were enriched with anti-hCD34 microbeads. Annexin V/PI staining of primary FLT3-ITD⁺ AML cells from Patient #5 (d) and FLT3-TKD⁺ AML cells from Patient #6 (e) treated with increasing concentrations of HPA-12 for 48 h. Annexin V/PI staining of primary FLT3-ITD + AML cells from Patient #5 (f) and FLT3-TKD + AML cells from Patient #6 (g) treated with with HPA-12 (80 µM) and Creno (6 µM) alone or in combination for 48 h. h Expression of GRP78, ATF6, and CHOP determined by western blotting of primary FLT3-ITD⁺ AML cells from Patient #5 in (h). Expression of GRP78 and ATF6 determined by western blotting in primary FLT3-TKD⁺ AML cells from Patient #6 (i) and primary FLT3-ITD⁺ AML cells from Patient #7 (j). The data are presented as the means ± SDs. The characteristics of the AML patients and healthy donors in this figure are shown in Table S9–10. Source data are provided as a source data file.